Anti-lpa Antibody (MOM-18426)
|Recombinant Anti-Human lpa Antibody
- Product Overview
- Recombinant Mouse Antibody is specific to Human LPA, expressed in Chinese Hamster Ovary cells(CHO)
- Recombinant Human Lipoprotein a (P08519).
- Suitable for use in Neut, ELISA, IF, IP, FuncS, FC, ICC and most other immunological methods.
- Specific Activity
- Tested positive against native antigen.
- >95.0%, determined by analysis by RP-HPLC & analysis by SDS-PAGE.
- At -20°C for one year.
- Antigen Description
- Lipoprotein(a) (Lp(a)) is a lipoprotein subclass assembled in the blood from low density lipoprotein (LDL) molecules and apolipoprotein-a (apo-a). Lp(a) recruits inflammatory cells through interaction with Mac-1 integrin. High Lp(a) in blood is a risk factor for coronary heart disease, cerebrovascular disease, atherosclerosis, thrombosis, and stroke. Lp(a) concentrations may be affected by disease states, but are only moderately affected by diet, exercise and other environmental factors. Lipid-reducing drugs have no effect on Lp(a) concentration. High Lp(a) predicts risk of early atherosclerosis similar to high LDL, but in advanced atherosclerosis, Lp(a) is a risk factor independent of LDL, indicating a coagulant risk of plaque thrombosis. Apo(a) contains domains that are very similar to plasminogen (PLG). Lp(a) accumulates in the vessel wall and inhibits binding of PLG to the cell surface, reducing plasmin generation which increases clotting. This inhibition also promotes proliferation of smooth muscle cells. These unique features of Lp(a) suggest a role in the generation of clots and atherosclerosis.
- apolipoprotein binding; endopeptidase inhibitor activity; fibronectin binding; heparin binding; peptidase activity; serine-type endopeptidase activity;
- LPA; lipoprotein, Lp(a); LP; apolipoprotein(a); lp(a); apo(a); antiangiogenic AK38 protein; AK38; APOA
All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.